Skip to main content
Clinical Trials/ISRCTN12578022
ISRCTN12578022
Completed
未知

A randomized, double-blind, controlled trial to evaluate the effect of esketamine on postoperative depressive symptoms in breast cancer patients undergoing modified radical mastectomy (Esketamine in Breast Cancer-Depression Randomized Trial)

The First Affiliated Hospital of University of South China0 sites108 target enrollmentAugust 25, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Breast cancer with postoperative depressive symptoms
Sponsor
The First Affiliated Hospital of University of South China
Enrollment
108
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 25, 2024
End Date
October 1, 2023
Last Updated
last year
Study Type
Interventional
Sex
Female

Investigators

Sponsor
The First Affiliated Hospital of University of South China

Eligibility Criteria

Inclusion Criteria

  • 1\. HAMD\-17 score between 8 and 24 (mild to severe depressive symptoms)
  • 2\. Age range between 18 and 65 years
  • 3\. American Society of Anesthesiologists (ASA) physical status classification of I\-II
  • 4\. Confirmed diagnosis of breast cancer and planned unilateral radical mastectomy for breast cancer

Exclusion Criteria

  • 1\. HAMD\-17 score of greater than 24 or less than 7
  • 2\. Other psychiatric disorders (e.g., schizophrenia and bipolar disorder)
  • 3\. History of psychiatric disorders prior to the study
  • 4\. Patients who have used psychotropic medications or have other serious systemic illnesses (including serious heart, kidney, or liver disease)
  • 5\. Contraindication or allergy to the use of esketamine
  • 6\. Planned surgery other than radical mastectomy alone (e.g., reconstruction)

Outcomes

Primary Outcomes

Not specified

Similar Trials